Showing results (1191-1200 of 1,427) with videos related to

Sort By:
Pageof 143
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2011
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials GroupAmit M Oza, Laurie Elit, Ming-Sound Tsao, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2019
TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analysesVictoria Mandilaras, Swati Garg, Michael Cabanero, et al.
Targeted Oncology|June 6, 2023
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid TumorsTodd M Bauer, Kathleen N Moore, Janet S Rader, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2012
Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for childrenRiyadh D Muhammad, Reena Oza-Frank, Elizabeth Zell, et al.
Gynecologic Oncology|April 8, 2023
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trialSandro Pignata, Amit Oza, Geoff Hall, et al.
Obstetrics and Gynecology International|June 12, 2018
Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary PerspectiveYeh Chen Lee, Nazlin Jivraj, Catherine O'Brien, et al.
The Lancet. Global Health|May 18, 2019
National, regional, and state-level all-cause and cause-specific under-5 mortality in India in 2000-15: a systematic analysis with implications for the Sustainable Development GoalsLi Liu, Yue Chu, Shefali Oza, et al.
Cancer Research Communications|March 27, 2023
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair DefectsMansoor Raza Mirza, Gabriel Lindahl, Sven Mahner, et al.
Gynecologic Oncology|December 15, 2019
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS)F T Roncolato, R L O'Connell, F Joly, et al.
The Lancet. Oncology|October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trialSusana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.
Pageof 143